John Paulson Has A Plan To Rescue His Biggest Stock Position, And Bill Ackman Won't Like It
The hedge fund, which is Allergan's third largest shareholder, told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.
The deal would not be structured as a so-called tax inversion, the people said. It could not be learned whether Allergan would pursue such a deal.
Back in June, Paulson had a totally different view on who Allergan should merge with. At CNBC's Delivering Alpha Conference he said that Allergan should sell itself to Valeant, a deal that is also supported (financially) by Paulson's fellow hedge fund manager, Bill Ackman.
So far Allergan has resisted Valeant's advances and indicated that it's looking for another buyer. Allergan argues that Valeant has no organic growth and uses its acquisitions to hide that fact. Short-seller Jim Chanos has made the same argument, calling Valeant an accounting roll-up.
Paulson's new plan for Shire comes as fellow pharmaceutical company AbbVie's $54 billion deal to buy Shire is close to unraveling after the U.S. government changed the rules governing tax inversions.
Paulson suffered over $780 million in paper losses after that news broke last week.
Allergan and Paulson declined to comment.
- Retail, real estate and religion: Spiritual hotspots brace for a tourism boom
- Move over K-beauty, Japanese brands are here to take over India’s clean B-trend
- MGNREGA wages get a 3-10% hike, average pay to go up by ₹28/day
- Most runs to most sixes – SRH vs MI IPL match shatters multiple records
- VC firm Accel to nurture eight early-stage startups in India